Streetbeat News

Products Services

SYK

Stryker (NYSE:SYK), a leading medical technology company, has launched its Q Guidance System with Cranial Guidance Software. The system provides surgeons with an image-based planning and intraoperative guidance system for cranial surgery. The software can be used for various procedures including craniotomies, skull base and transsphenoidal procedures, shunt placements, and biopsies. The system uses both active and passive tracking technology to provide planning and guidance capabilities.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 12:48 pm

ADCT

ADC Therapeutics SA has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta and rituximab in patients with untreated diffuse large B-cell lymphoma. This decision comes after a review of data from the 40 patients enrolled in the trial, which indicated potentially excessive respiratory-related events. The company does not expect to report additional data from the trial by the end of the year. ADCT shares are down 15.60% at $2.00 during the premarket session.

Portfolio Pulse from Vandana Singh

July 11, 2023 | 12:47 pm

NVVE

Nuvve Corporation has integrated artificial intelligence into its GIVe software platform via the FleetBox Charge Management App. The AI will help reduce charging costs and improve customer experience by advancing fleet vehicle forecasting with improved trip automation recommendations and enhanced scheduling predictions.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:47 pm

DDD

3D Systems (NYSE:DDD) and Oerlikon AM have entered a collaboration agreement to scale metal additive manufacturing. The collaboration aims to catalyze metal AM applications in high-criticality markets such as semiconductor and aerospace. As part of the agreement, Oerlikon AM is acquiring its fourth 3D Systems DMP Factory 500 system, the first in the U.S., to be part of the manufacturing workflow in its North Carolina facility.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 12:47 pm

ADCT

ADC Therapeutics has paused enrollment in its Phase 2 LOTIS-9 trial of Zynlonta and rituximab in unfit or frail patients with previously untreated diffuse large b-cell lymphoma. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:46 pm

CVM

CEL-SCI has reported Phase 3 tumor PD-L1 biomarker data showing increased efficacy of Multikine and its potential for combination with checkpoint inhibitors for head and neck cancer. The company has filed a patent for the use of Multikine in tumors expressing low levels of PD-L1.

Portfolio Pulse from Benzinga Newsdesk

July 11, 2023 | 12:46 pm

ITI

Iteris, Inc. (NASDAQ:ITI) has been awarded a three-year, $1.3 million SaaS contract by the Los Angeles County Metropolitan Transportation Authority (LA Metro) for the continued use of ClearGuide, a technology that provides transportation analytics to support mobility and safety applications. The contract demonstrates LA Metro's confidence in ClearGuide and Iteris' services.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 12:44 pm

ADEA

Adeia Inc. (NASDAQ:ADEA) has renewed its agreement with Enseo, LLC, a technology services provider for the hospitality industry, to license Adeia's media intellectual property portfolio. Enseo provides technology solutions that improve the in-room digital entertainment experience of hotel and resort guests. The agreement validates Adeia's market-leading technology as an enabler of digital entertainment experiences in the hospitality industry.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 12:43 pm

ADIL

Adial Pharmaceuticals has received positive feedback from US and EU regulators regarding the development of AD04, a treatment for Alcohol Use Disorder (AUD). The regulators acknowledged the importance of ongoing research in the AUD therapeutic area and confirmed the primary US endpoint based on Percentage of No Heavy Drinking Days. Adial plans to focus its efforts on the US, as the US standards should translate to acceptance in other international markets. The company expects to register AD04 with the FDA in Q3 of 2025, with the trials costing approximately $25 million in total.

Portfolio Pulse from Happy Mohamed

July 11, 2023 | 12:43 pm

PLTR

Shares of Palantir Technologies Inc (NYSE:PLTR) have risen nearly 90% over the last three months, with the rally accelerating after the company reported better-than-expected quarterly results and guided for continued profitability in each quarter of 2023. The company has seen strong demand for its new AI platform, and its shares are up more than 150% year-to-date. Palantir held its first ever AIPCon in June, where CEO Alex Karp highlighted the unprecedented demand for its AI products.

Portfolio Pulse from Adam Eckert

July 11, 2023 | 12:38 pm